Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents

被引：15
|
作者：
Liu, Shangde [1 ]
Li, Shanshan [1 ]
Yuan, Duo [1 ]
Wang, Enmao [1 ]
Xie, Roujie [1 ]
Zhang, Weiqi [1 ]
Kong, Yi [2 ]
Zhu, Xiong [1 ]
机构：
[1] China Pharmaceut Univ, Inst Med & Chem, Nanjing 210009, Peoples R China
[2] China Pharmaceut Univ, Sch Life & Technol, Nanjing 210009, Peoples R China
来源：
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2021年 / 209卷
关键词：
PAR4; Small-molecule antagonists; Antiplatelet agents; SAR; Structural optimization; BMS-986120; BMS-986141; Preclinical trials; Clinical trials; ACUTE CORONARY SYNDROMES; THROMBIN-RECEPTOR; PLATELET ACTIVATION; THROMBOXANE PRODUCTION; IN-VITRO; INHIBITION; YD-3; AGGREGATION; DISCOVERY; PEPTIDES;
D O I：
10.1016/j.ejmech.2020.112893
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Protease activated receptor 4 (PAR4) is a key target in antiplatelet medication to reduce the risk of heart attack and thrombotic complications in stroke. PAR4 antagonists can prevent harmful and stable thrombus growth while retaining initial thrombus formation by acting on the late diffusion stage of platelet activation, which may provide a safer alternative than other antiplatelet agents. Currently, research on PAR4 antagonists is of increasing interest in the field of antiplatelet agents. This article provides an overview of the discovery and development of small-molecule antagonists of PAR4 as novel antiplatelet agents, including structure-activity relationship (SAR) analysis, progress of structure and bioassay optimization, and the latest structural and/or clinical information of representative small-molecule antagonists of PAR4. (c) 2020 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数：15
相关论文
共 30 条
  • [1] Protease-Activated Receptor 4 (PAR4): A Promising Target for Antiplatelet Therapy
    Rudinga, Gamariel Rwibasira
    Khan, Ghulam Jilany
    Kong, Yi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (02)
  • [2] PAR4 (Protease-Activated Receptor 4) PARticularly Important 4 Antiplatelet Therapy
    Han, Xu
    Nieman, Marvin T.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38 (02) : 287 - 289
  • [3] Synthesis and evaluation of novel and potent protease activated receptor 4 (PAR4) antagonists based on a quinazolin-4(3H)-one scaffold
    Liu, Shangde
    Yuan, Duo
    Li, Shanshan
    Xie, Roujie
    Kong, Yi
    Zhu, Xiong
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 225
  • [4] Discovery of Protease-Activated Receptor 4 (PAR4)-Tethered Ligand Antagonists Using Ultralarge Virtual Screening
    Smith, Shannon T.
    Cassada, Jackson B.
    Von Bredow, Lukas
    Erreger, Kevin
    Webb, Emma M.
    Trombley, Trevor A.
    Kalbfleisch, Jacob J.
    Bender, Brian J.
    Zagol-Ikapitte, Irene
    Kramlinger, Valerie M.
    Bouchard, Jacob L.
    Mitchell, Sidnee G.
    Tretbar, Maik
    Shoichet, Brian K.
    Lindsley, Craig W.
    Meiler, Jens
    Hamm, Heidi E.
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2024, 7 (04) : 1086 - 1100
  • [5] Development and characterization of monoclonal antibodies against Protease Activated Receptor 4 (PAR4)
    Mumaw, Michele M.
    de la Fuente, Maria
    Arachiche, Amal
    Wahl, James K., III
    Nieman, Marvin T.
    THROMBOSIS RESEARCH, 2015, 135 (06) : 1165 - 1171
  • [6] Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding
    Wong, Pancras C.
    Seiffert, Dietmar
    Bird, J. Eileen
    Watson, Carol A.
    Bostwick, Jeffrey S.
    Giancarli, Mary
    Allegretto, Nick
    Hua, Ji
    Harden, David
    Guay, Jocelyne
    Callejo, Mario
    Miller, Michael M.
    Lawrence, R. Michael
    Banville, Jacques
    Guy, Julia
    Maxwell, Brad D.
    Priestley, E. Scott
    Marinier, Anne
    Wexler, Ruth R.
    Bouvier, Michel
    Gordon, David A.
    Schumacher, William A.
    Yang, Jing
    SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (371)
  • [7] Selective Inhibition of PAR4 (Protease-Activated Receptor 4)-Mediated Platelet Activation by a Synthetic Nonanticoagulant Heparin Analog
    Lin, Yu-Chuan
    Ko, Yen-Chun
    Hung, Shang-Cheng
    Lin, Ying-Ting
    Lee, Jia-Hau
    Tsai, Ju-Ying
    Kung, Po-Hsiung
    Tsai, Meng-Chun
    Chen, Yih-Fung
    Wu, Chin-Chung
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2019, 39 (04) : 694 - 703
  • [8] Mapping Human Protease-activated Receptor 4 (PAR4) Homodimer Interface to Transmembrane Helix 4
    de la Fuente, Maria
    Noble, Daniel N.
    Verma, Sheetal
    Nieman, Marvin T.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (13) : 10414 - 10423
  • [9] Expression and Purification of Protease-Activated Receptor 4 (PAR4) and Analysis with Histidine Hydrogen-Deuterium Exchange
    de la Fuente, Maria
    Han, Xu
    Miyagi, Masaru
    Nieman, Marvin T.
    BIOCHEMISTRY, 2020, 59 (05) : 671 - 681
  • [10] Inhibitors of protease-activated receptor 4 (PAR4): a review of recent patents (2013-2021)
    Yu, Xiangying
    Li, Shanshan
    Zhu, Xiong
    Kong, Yi
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2022, 32 (02) : 153 - 170
123